Global Chlamydia Market Insights 2029: Drivers, Challenges, and Revenue Forecast
Claim your 20% discount on Global Market Reports with code ONLINE20. Limited time only.
What Is The Predicted Market Size Of The Chlamydia Industry By 2029?
The market size for chlamydia has seen robust growth in recent years. It is set to expand from $2.97 billion in 2024 to $3.23 billion in 2025, with a Compound Annual Growth Rate (CAGR) of 8.7%. Factors contributing to this growth during the historic period include an increase in sexual health education programs, a growing demand for rapid diagnostic tests, as well as a rise in the need for affordable and scalable solutions for STI diagnostics. Additionally, the burgeoning domain of telemedicine and a heightened focus on precision medicine have also contributed to the market’s expansion.
Anticipations are high for a robust expansion of the chlamydia market in the coming years. The market is projected to reach up to $4.49 billion by 2029, growing at a compound annual growth rate (CAGR) of 8.6%. This anticipated growth during the forecast period can be linked to the rising incidences of chlamydia, heightened public consciousness, an increase in point-of-care testing alternatives, a growing rate of sexually transmitted diseases, and enhanced investment in research and development. Noteworthy trends projected for the forecast period include a transition towards point-of-care testing, advances in molecular diagnostics, a focus on preventative healthcare, the incorporation of artificial intelligence (AI) in diagnostics, and the evolution of high-throughput screening platforms.
Get A Free Sample Of The Report:
https://www.thebusinessresearchcompany.com/sample.aspx?id=21138&type=smp
Which Industry Forces Are Driving The Chlamydia Market Forward?
The upward trend in sexually transmitted diseases is anticipated to drive the expansion of the chlamydia market. Infections such as chlamydia, gonorrhea, and HIV, which are transferred through sexual interaction, are referred to as sexually transmitted diseases (STDs). The escalating rate of STDs can be related to factors like reduced use of condoms, inadequate knowledge, restricted access to health services, and the popularity of dating apps encouraging multiple sexual partners. Chlamydia treatment is crucial in mitigating the spread of STDs by eradicating the infection, averting potential complications, and minimizing the chances of transferring the disease to sexual partners. As reported by the National Association of County and City Health Officials, a non-profit organization based in the US, more than 2.5 million cases of syphilis, gonorrhea, and chlamydia were registered in the U.S. in 2022 alone. While syphilis cases surged by 80%, congenital syphilis cases saw a staggering increase of 937%. Around 3,755 instances of congenital syphilis were documented, indicating a 31% rise from 2021 to 2022. Therefore, the escalating occurrence of sexually transmitted diseases is fuelling the growth of the chlamydia market.
What Is The Segment Breakdown Of The Chlamydia Market?
The chlamydiamarket covered in this report is segmented –
1) By Test Type: Culture Tests; Nucleic Acid Amplification Test (NAAT); Direct Fluorescent Antibody Test; Serology Tests; Other Test Types
2) By Route Of Administration: Oral; Injectable; Other Routes Of Administration
3) By End User: Hospitals; Diagnostic Centers; Ambulatory Surgical Centers; Other End Users
Subsegments:
1) By Culture Tests: Urethral Swab Culture; Endocervical Swab Culture; Urine Culture Test; Conjunctival Swab Culture
2) By Nucleic Acid Amplification Test (NAAT): PCR (Polymerase Chain Reaction); Transcription-Mediated Amplification (TMA); Strand Displacement Amplification (SDA); Loop-Mediated Isothermal Amplification (LAMP)
3) By Direct Fluorescent Antibody Test: DFA Test For Urogenital Chlamydia; DFA Test For Ocular Chlamydia; DFA For Respiratory Chlamydia Detection
4) By Serology Tests: Enzyme-Linked Immunosorbent Assay (ELISA); Immunofluorescence Assay (IFA); Western Blot
5) By Other Test Types: Immunochromatographic Rapid Test; Lateral Flow Immunoassay; Hybrid Capture Test (HCT)
How Are Global Trends Impacting The Development Of The Chlamydia Market?
Leading entities in the chlamydia market are prioritizing the development of wholly automated tools to boost the accuracy of diagnostics, mitigate the risk of human mistakes, and increase the speed of testing. An entirely automated tool can perform tasks independently without requiring human involvement, typically leveraging sensors, control mechanisms, and artificial intelligence for its autonomous functions. For example, in May 2022, the American medical device company BD (Becton, Dickinson and Company), inaugurated the BD COR MX/PX System. The BD CTGCTV2 molecular assay, the first test present on this new system, identifies the three most frequently occurring non-viral sexually transmitted infections (STIs)—chlamydia trachomatis (CT), neisseria gonorrhoeae (GC), and trichomonas vaginalis (TV). These STIs may induce various adverse health impacts in patients, such as complications during pregnancy and an escalated likelihood of contracting HIV.
Which Companies Are Contributing Significantly To The Chlamydia Market Growth?
Major companies operating in the chlamydia market are Pfizer Inc., Siemens Healthineers, F. Hoffmann-La Roche Ltd, Merck & Co. Inc., Thermo Fisher Scientific Inc., AstraZeneca, Abbott Laboratories, GlaxoSmithKline Plc, Gilead Sciences Inc., Danaher Corporation, Becton, Dickinson and Company, Hologic Inc., Quidel Corporation, Bio-Rad Laboratories Inc., Ortho Clinical Diagnostics, DiaSorin SpA, Eiken Chemical Co. Ltd., MedMira Inc., GenMark Diagnostics Inc., Aytu BioScience Inc., ACON Laboratories, Inc., Biocartis Group NV, Inova Diagnostics Inc., Trinity Biotech Plc, Laxai Pharma Ltd.
Access The Complete Report Here:
https://www.thebusinessresearchcompany.com/report/chlamydia-global-market-report
Which Region Is Leading Innovation In The Chlamydia Market?
North America was the largest region in the chlamydia market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the chlamydia market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Customize Your Report Here:
https://www.thebusinessresearchcompany.com/customise?id=21138&type=smp
Browse Through More Reports Similar to the Global Chlamydia Market 2025, By The Business Research Company
Sexually Transmitted Infections Stis Global Market Report 2025
Inflammatory Bowel Disease Treatment Global Market Report 2025
Non Steroidal Anti Inflammatory Drugs Global Market Report 2025
About The Business Research Company:
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 310-496-7795
Asia +44 7882 955267 & +91 8897263534
Europe +44 7882 955267
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
